Safety Issues Clinical Trial
Official title:
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
Despite state-of-the-art advances in the treatment of acute myocardial infarction (AMI), including early and prompt reperfusion therapy and advanced pharmaceutical therapy, AMI remains the leading cause of death of patients hospitalized for cardiovascular disease. Loss of myocardium after AMI, resulting in reducing LVEF and ultimately pump failure, are essential for unfavorable clinical outcomes and mortality, highlighting that to protect the myocardium from AMI-induced damage is the principal rule for treatment of the AMI patients. The pathological findings have clearly identified that loss of myocardium after AMI results from first ischemic necrosis, followed by ischemia-reperfusion injury, vigorous inflammatory reaction, generation of oxidative stress, and finally, upregulation of immune reaction. Thus, a phenomenon of "propagation of myocardium from injury to irrepressible death" at the moment just after AMI always occurs. These are the reasons why a satisfactory therapy for AMI is still difficult, highlighting the timing remains the Achilles' heel for salving the jeopardized myocardium. These raise the consideration of urgently to develop a new effective and safe treatment for patients. Abundant data have shown mesenchymal stromal cells (MSC) pleiotropic capacities of anti-inflammation, immunomodulation, and tissue regeneration. Experimental studies have further demonstrated that MSC therapy effectively protected the organs from ischemic/ischemia-reperfusion injury. However, the therapeutic impact of stem cells on the clinical setting of AMI is still universally controversial. When investigators further look at the clinical trials, delayed time to apply the stem cells on AMI patients is universally consistent. Investigators have demonstrated that early intracoronary administration (i.e., at the time interval of 90 minutes after AMI induction) of OmniMSC-AMI significantly protected the left ventricular myocardium and improved LVEF in the mini-pig AMI model. The aforementioned issues and the results of our experimental study may support our hypothesis that immediate intracoronary administration of OmniMSC-AMI into the infarcted-related vessel in first AMI patients who just yet underwent primary PCI will be safe and may offer benefits in improving LVEF and outcome. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
| Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
| Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
| Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
| Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
| Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
| Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
| Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
| Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
| Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
| Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
| Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
| Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
| Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
| Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
| Withdrawn |
NCT04759066 -
The HEALiX™ Intubated Patient (IP) Pilot Study
|
N/A |